Petro Terblanche, Afrigen Biologics managing director (Kristin Palitza/picture-alliance/dpa/AP Images)

WHO-backed Afrigen plans a charge to­ward the clin­ic with Africa's first Covid-19 vac­cine

NEW YORK — When vac­cines from high-in­come coun­tries did not ar­rive in Africa, a lo­cal WHO-backed com­pa­ny de­cid­ed to take the mat­ter in­to its own hands.

The South Africa-based com­pa­ny Afrigen Bi­o­log­ics and Vac­cines has de­vel­oped the con­ti­nent’s first mR­NA Covid-19 vac­cine that will en­ter clin­i­cal tri­als in ear­ly 2023. Afrigen de­vel­oped the shot by copy­ing pub­licly avail­able se­quenc­ing in­for­ma­tion about Mod­er­na’s shot af­ter the biotech and Pfiz­er re­fused as­sis­tance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.